Connect with us

Health

New cannabinoid treatments to focus on mental health

Published

on

Some studies have already shown promise in the effectiveness of cannabinoids when it comes to treating conditions like anxiety and PTSD

New formulations of cannabinoid treatments are being developed to focus on women’s health and mental illness as the pandemic adds pressure to tackle the mental health crisis.

Research company, Spectral Analytics Precision Tele-Monitoring, which focuses on supplementation of the endocannabinoid system, has begun developing new formulations designed to help patients with mental health and women’s health issues.

The new formulations will be developed to help those particularly struggling to overcome PTS, depression, ADHD, bi-polar, endometriosis, immunodeficiency, and weight management.

It comes as the coronavirus pandemic creates a growing demand for mental health awareness and the need for clinical research to develop more effective formulations is greater than ever before.

A recent survey from the Centers for Disease Control (CDC) showed that from June 24-30, 2020, adults in the US reported “considerably elevated adverse mental health conditions associated with COVID-19.” 

The CDC survey also found that 40.9 percent of 5,470 respondents reported an adverse mental or behavioral health condition, including symptoms of anxiety disorder or depressive disorder, trauma-related symptoms, new or increased substance use, or thoughts of suicide. 

Christina DiArcangelo, CEO of Spectral Analytics Precision Tele-Monitoring commented: “I am so very pleased to announce our focus in mental health and women’s health phytocannabinoid treatments. 

“We are shining a light on the fact that this patient population has been forgotten in drug development.” 

DiArcangelo added: “In addition, with the negative impacts this pandemic has had on mental health, we feel a responsibility to step up and provide relief.”

Spectral Analytics Precision Tele-Monitoring is a nutraceutical research company with the fundamental premise that phytocannabinoid supplementation of the endocannabinoid system through the use of cannabinoids and other nutraceuticals will improve health.

The company is hoping to have its first round of formulations complete by late spring/summer 2021.

Sarah Sinclair is a respected cannabis journalist writing on subjects related to science, medicine, research, health and wellness. She is managing editor of Cannabis Health, the UK’s leading title covering medical cannabis and CBD, and sister title and Psychedelic Health. Sarah has an NCTJ journalism qualification and an MA in Journalism from the University of Sunderland. Sarah has over six years experience working on newspapers, magazines and digital-first titles, the last two of which have been in the cannabis sector. She has also completed training through the Medical Cannabis Clinicians Society securing a certificate in Medical Cannabis Explained. She is a member of PLEA’s (Patient-Led Engagement for Access) advisory board, has hosted several webinars on cannabis and women's health and has moderated at industry events such as Cannabis Europa. Sarah Sinclair is the editor of Cannabis Health. Got a story? Email sarah@prohibitionpartners.com / Follow us on Twitter: @CannabisHNews / Instagram: @cannabishealthmag

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2024 PP Intelligence Ltd.